Senticell
Senticell is developing a liquid-biopsy diagnostic based on nucleic acids associated with red blood cells.
$7MSeed
ParticipantEC
Evoce Capital
Activity from announced rounds
Activity in this selectionOct 16, 2026 · Jul 19, 2026
Evoce Capital is the investment firm named in Surf Therapeutics and Senticell financing histories.
Recorded funding activity
Surf develops non-invasive ultrasound neuromodulation for immune-mediated diseases. Senticell develops a liquid-biopsy diagnostic using nucleic acids associated with red blood cells. The companies pursue different therapeutic and diagnostic approaches rather than the same product.
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $7M 1 disclosed · full round size, not this investor’s share